Checkpoint Therapeutics Inc (NASDAQ:CKPT) has a beta value of 1.29 and has seen 2.32 million shares traded in the last trading session. The company, currently valued at $212.67M, closed the last trade at $4.03 per share which meant it gained $0.28 on the day or 7.47% during that session. The CKPT stock price is 1.49% off its 52-week high price of $3.97 and 66.25% above the 52-week low of $1.36. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.77 million shares traded. The 3-month trading volume is 676.27K shares.
The consensus among analysts is that Checkpoint Therapeutics Inc (CKPT) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information
Sporting 7.47% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CKPT stock price touched $4.03 or saw a rise of 5.62%. Year-to-date, Checkpoint Therapeutics Inc shares have moved 75.98%, while the 5-day performance has seen it change 22.12%. Over the past 30 days, the shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) have changed 9.81%. Short interest in the company has seen 5.56 million shares shorted with days to cover at 5.7.
Checkpoint Therapeutics Inc (CKPT) estimates and forecasts
Figures show that Checkpoint Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 125.14% over the past 6 months, with this year growth rate of 71.29%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be -76.70%.
3 analysts offering their estimates for the company have set an average revenue estimate of 10.33k for the current quarter. 1 have an estimated revenue figure of 4.53M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 26.32% over the past 5 years.
CKPT Dividends
Checkpoint Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s Major holders
Insiders own 15.52% of the company shares, while shares held by institutions stand at 13.91% with a share float percentage of 16.47%. Investors are also buoyed by the number of investors in a company, with Checkpoint Therapeutics Inc having a total of 50.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Jun 30, 2024 , the former fund manager holds about 2.27% shares in the company for having 1.09 shares of worth $4.4 million while later fund manager owns 242.15 shares of worth $0.98 million as of Jun 30, 2024 , which makes it owner of about 0.50% of company’s outstanding stock.
